MeiraGTx (MGTX) Expected to Post Earnings on Thursday

Key Points

• MeiraGTx is expected to report Q3 2026 results before markets open on November 12. Analysts forecast a loss of $0.46 per share and revenue of $6.95 million; the earnings call is scheduled for November 13.
• In its previous quarter, the company reported EPS of $1.71, beating the $0.46-per-share loss consensus, and revenue of $321.43 million versus analysts’ $0.70 million estimate.
• Analysts give the stock a Moderate Buy consensus rating with a $24 average price target. Company insiders sold a combined 145,659 shares over the past 90 days.

MeiraGTx (NASDAQ:MGTX - Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $6.95 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported $1.71 EPS for the quarter, beating the consensus estimate of ($0.46) by $2.17. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%. The company had revenue of $321.43 million during the quarter, compared to the consensus estimate of $0.70 million. On average, analysts expect MeiraGTx to post $0.30 EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

MeiraGTx Stock Down 1.1%

MGTX stock opened at $9.42 on Thursday. The stock's 50 day moving average is $11.40 and its 200-day moving average is $10.32. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $904.70 million, a PE ratio of 13.27 and a beta of 1.09. MeiraGTx has a twelve month low of $6.62 and a twelve month high of $15.35.

Insiders Place Their Bets

In other MeiraGTx news, CEO Alexandria Forbes sold 62,000 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $13.86, for a total transaction of $859,320.00. Following the sale, the chief executive officer directly owned 1,325,695 shares in the company, valued at $18,374,132.70. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of MeiraGTx stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $10.64, for a total transaction of $294,291.76. Following the transaction, the insider directly owned 613,187 shares of the company's stock, valued at approximately $6,524,309.68. This represents a 4.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 145,659 shares of company stock valued at $1,710,812 over the last ninety days. 7.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada increased their target price on shares of MeiraGTx from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Friday, August 14th. Zacks Research downgraded shares of MeiraGTx from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 11th. The Goldman Sachs Group assumed coverage on MeiraGTx in a research note on Thursday, September 24th. They issued a "neutral" rating and a $16.00 price target on the stock. Wall Street Zen upgraded shares of MeiraGTx from a "hold" rating to a "buy" rating in a research note on Saturday, October 24th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of MeiraGTx in a report on Wednesday, July 8th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, MeiraGTx currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes to targeted tissues and address the underlying causes of disease.

Its research and development activities have focused primarily on disorders of the central nervous system, including neurodegenerative diseases, as well as retinal and salivary-gland conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.